trending Market Intelligence /marketintelligence/en/news-insights/trending/wkp77ajI4Zs0X8OL4Z7ydA2 content esgSubNav
In This List

Organovo to suspend lead liver drug candidate, explore strategic alternatives

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Organovo to suspend lead liver drug candidate, explore strategic alternatives

Organovo Holdings Inc. is exploring strategic alternatives and a restructuring program to significantly reduce expenses, following the board of directors' decision to discontinue its lead liver drug candidate.

Organovo's stock plunged about 30.3% to 27 cents as of 1:58 p.m. ET on Aug. 7.

Roth Capital Partners will be the San Diego, Calif.-based biotechnology company's financial adviser in the process, Organovo said in its Aug. 7 press release.

According to Organovo, the lead liver program was suspended due to insufficient data supporting its therapeutic benefit, and the development challenges and timeline would not have returned sufficient value to shareholders.

Potential strategic alternatives could include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction.